William M Pardridge
Overview
Explore the profile of William M Pardridge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
168
Citations
7156
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pardridge W
Front Aging Neurosci
. 2023 Nov;
15:1276376.
PMID: 38035276
Parkinson's disease (PD) is characterized by neurodegeneration of nigral-striatal neurons in parallel with the formation of intra-neuronal α-synuclein aggregates, and these processes are exacerbated by neuro-inflammation. All 3 components of...
2.
Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier
Pardridge W
Front Drug Deliv
. 2023 Aug;
3.
PMID: 37583474
Therapeutic antibody drug development is a rapidly growing sector of the pharmaceutical industry. However, antibody drug development for the brain is a technical challenge, and therapeutic antibodies for the central...
3.
Pardridge W
Trends Mol Med
. 2023 Mar;
29(5):343-353.
PMID: 36907687
The COVID-19 mRNA vaccine was developed by the scalable manufacture of lipid nanoparticles (LNPs) that encapsulate mRNA within the lipid. There are many potential applications for this large nucleic acid...
4.
Pardridge W
Pharm Res
. 2023 Feb;
40(3):661-674.
PMID: 36829100
Introduction: A physiologically based pharmacokinetic (PBPK) model is developed that focuses on the kinetic parameters of drug association and dissociation with albumin, alpha-1 acid glycoprotein (AGP), and brain tissue proteins,...
5.
Pardridge W
Pharmaceutics
. 2023 Jan;
15(1).
PMID: 36678722
This Special Issue of Pharmaceutics, "Advanced Blood-Brain Barrier Drug Delivery," comprises 16 articles or reviews, which cover a cross-section of brain drug delivery for either small-molecule or large-molecule therapeutics [...].
6.
Hahn A, Sato Y, Ikeda T, Sonoda H, Schmidt M, Pfrimmer C, et al.
Mol Genet Metab Rep
. 2022 Nov;
33:100930.
PMID: 36324638
Neuronal ceroid lipofuscinosis type 1(CLN1 disease) is a rare autosomal recessive lysosomal storage disease caused by genetic defects of palmitoyl protein thioesterase-1(), leading to accumulation of lipofuscin granules in brain...
7.
Pardridge W
Pharmaceutics
. 2022 Jun;
14(6).
PMID: 35745855
The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914, that a drug for syphilis, salvarsan, did not enter the brain, due to the presence...
8.
Pardridge W
Adv Drug Deliv Rev
. 2022 May;
15(1-3):5-36.
PMID: 35524389
The development of small molecules as effective neuropharmaceuticals requires that these compounds undergo significant transport through the brain capillary endothelial wall, which makes up the blood-brain barrier (BBB) in vivo....
9.
Pardridge W
Adv Drug Deliv Rev
. 2022 May;
15(1-3):109-146.
PMID: 35524386
Peptides are potential new CNS pharmaceuticals should these highly water soluble compounds be made transportable through the brain capillary endothelial wall, which makes up the blood-brain barrier (BBB) in vivo....
10.